Skip directly to content

XELJANZ® (tofacitinib citrate) Product Information | Safety Info

Product Information

Find Prescribing Information resources and video describing how JAK pathways
are related to the inflammatory process.

.
Full Prescribing Information and Medication Guide

Indication

  • XELJANZ® (tofacitinib citrate) 5-mg tablets/
    XELJANZ® XR (tofacitinib citrate)
    extended-release 11-mg tablets is indicated for the
    treatment of adult patients with moderately to
    severely active rheumatoid arthritis who have had
    an inadequate response or intolerance to
    methotrexate. It may be used as monotherapy or
    in combination with methotrexate or
    other nonbiologic disease-modifying antirheumatic
    drugs (DMARDs).
  • Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
.

Dosing and Administration Recommendations

XELJANZ and XELJANZ XR are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Click on the dosing guide to review additional dosing and administration considerations.

View Full Dosing and Administration Recommendations
.

JAK Pathway Video

  • Discovery and function
    of the JAK pathways

    Lionel B. Ivashkiv, MD
  • Mechanisms of disease
    in RA

    Peter C. Taylor, PhD
  • Cytokines and their role in
    the pathogenesis of RA

    Ian McInnes, PhD
.

Mechanism of Action

Tofacitinib is a small molecule
inhibitor of JAK enzymes. Discover how
inhibiting the JAK pathways reduces the
cytokine signaling that drives inflammation in
rheumatoid arthritis. Learn more about the
mechanism of action of tofacitinib.

View presentation
.
.